Skip to main content
. Author manuscript; available in PMC: 2016 Dec 20.
Published in final edited form as: N Engl J Med. 2016 Apr 7;374(14):1344–1355. doi: 10.1056/NEJMoa1500925

Table 1.

Characteristics of the Patients at Baseline.*

Characteristic Radiation Therapy Alone (N = 126) Radiation Therapy plus PCV (N = 125)
Median age — yr 40 41
Sex — no. (%)
 Male 77 (61) 65 (52)
 Female 49 (39) 60 (48)
Race or ethnic group — no. (%)
 White 116 (92) 111 (89)
 Hispanic 5 (4) 6 (5)
 Black 5 (4) 5 (4)
 Asian, American Indian, or Alaska Native 0 3 (2)
Karnofsky performance-status score — no. (%)
 60–80 33 (26) 31 (25)
 90 or 100 93 (74) 94 (75)
Neurologic function — no. (%)
 No symptoms 49 (39) 62 (50)
 Minor symptoms 67 (53) 49 (39)
 Moderate symptoms and fully active 5 (4) 10 (8)
 Moderate symptoms and not fully active 5 (4) 4 (3)
Extent of surgery — no. (%)
 Biopsy 59 (47) 60 (48)
 Partial resection 56 (44) 51 (41)
 Total resection 11 (9) 14 (11)
Histologic findings — no. (%)
 Astrocytoma 29 (23) 36 (29)
 Oligodendroglioma 57 (45) 50 (40)
 Oligoastrocytoma
  Astrocytoma features dominant 19 (15) 19 (15)
  Astrocytoma features equivalent to oligodendroglioma features 5 (4) 1 (1)
  Oligodendroglioma features dominant 16 (13) 19 (15)
IDH1 R132H mutation — no./total no. (%)
 Present 35/57 (61) 36/56 (64)
 Absent 22/57 (39) 20/56 (36)
MMSE score — no. (%)§
 <27 11 (9) 17 (14)
 27–30 111 (88) 99 (79)
 Not completed 4 (3) 9 (7)
*

There were no significant between-group differences at baseline. IDH1 denotes isocitrate dehydrogenase 1 gene, and PCV procarbazine, lomustine (also called CCNU), and vincristine.

Race or ethnic group was self-reported.

Karnofsky performance-status scores range from 0 to 100, with lower numbers indicating greater disability.

§

Scores on the Mini–Mental State Examination (MMSE) range from 0 to 30, with lower scores indicating poor cognitive performance. Scores of 27 to 30 are considered to be in the normal range; a score of less than 27 is considered to be abnormal.